MaxCyte Shareholders Approve Equity Plan Amendment

An update from MaxCyte ( (MXCT) ) is now available.

At the 2025 annual meeting held on June 18, MaxCyte‘s stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the authorized shares by 2,950,000. Additionally, all five proposals presented, including the election of directors and the ratification of CohnReznick LLP as the accounting firm, were approved, indicating strong shareholder support for the company’s strategic decisions.

The most recent analyst rating on (MXCT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.

Spark’s Take on MXCT Stock

According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.

MaxCyte’s overall score is impacted primarily by its financial challenges and weak technical indicators. Despite a strong equity position and promising SPL pipeline, persistent losses and negative cash flow weigh heavily. The negative market momentum and lack of dividend yield further detract from the stock’s attractiveness. Management’s confidence in their growth plan and strong cash reserves provide some support but are overshadowed by revenue declines and macroeconomic uncertainties.

To see Spark’s full report on MXCT stock, click here.

More about MaxCyte

MaxCyte, Inc. operates in the biotechnology industry, focusing on providing cell-engineering platform technologies. The company is known for its proprietary flow electroporation technology, which is used in drug discovery and development, biomanufacturing, and cell therapy.

Average Trading Volume: 885,160

Technical Sentiment Signal: Sell

Current Market Cap: $238.2M

See more data about MXCT stock on TipRanks’ Stock Analysis page.